Calidi Biotherapeutics (CLDI) Receivables (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Receivables of $50.0 billion for Q4 2025, up 24999900.0% year-over-year from N/an in Q4 2024, and up 99999900.0% quarter-over-quarter from $50000.0 in Q2 2025.
Calidi Biotherapeutics (CLDI) Receivables (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Receivables history runs 4 years deep, the most recent figure standing at $50.0 billion for Q4 2025.
- In Q4 2025, Receivables rose 24999900.0% year-over-year to $50.0 billion; the TTM figure through Dec 2025 stood at $50.0 billion (up 24999900.0% YoY), while the FY2025 annual figure was $50.0 billion, up 24999900.0% from the prior year.
- Receivables for Q4 2025 stood at $50.0 billion, up from $50000.0 in the prior quarter.
- The five-year high for Receivables was $50.0 billion in Q4 2025, with the low at $870.0 in Q2 2023.
- The 4-year median for Receivables is $200000.0 (2024), against an average of $6.3 billion.
- The sharpest annual moves came in 2024 and 2025: Receivables tumbled 93.1% in 2024, then soared 24999900.0% in 2025.
- Calidi Biotherapeutics' Receivables stood at $600870.0 in 2022, then surged by 382.63% to $2.9 million in 2023, then sank by 93.1% to $200000.0 in 2024, then jumped by 24999900.0% to $50.0 billion in 2025.
- Business Quant data shows CLDI's Receivables at $50.0 billion in Q4 2025, $50000.0 in Q2 2025, and $50000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.98 Mn | -2.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.00 Bn |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Dec 31, 2023 | 2.90 Mn |
| Jun 30, 2023 | 870.00 |
| Dec 31, 2022 | 600,870.00 |